Invitation to Submit Proposals under Agreement(s) 2023/438 - Human Plasma Derivatives, 2023/671 - Various Medicines and 2025/1589 - Various Medicines for the Acquisition of Plasma-Derived Medicines

This tender invites proposals for the acquisition of plasma-derived medicines under the agreements numbered 2023/438, 2023/671, and 2025/1589. The focus of this procurement is to secure various medicines derived from human plasma, which are essential for medical treatments and therapies. Interested parties are encouraged to submit their proposals in accordance with the specified agreements, which outline the requirements and conditions for participation. Key requirements may include compliance with regulatory standards for pharmaceutical products, quality assurance protocols, and the ability to deliver within stipulated timelines. The tender is aimed at suppliers and manufacturers who specialize in plasma-derived products and have the capacity to meet the demands of healthcare providers. The location for the delivery of these medicines will be specified in the detailed tender documents. This procurement is critical for ensuring the availability of necessary medical supplies in the healthcare sector, thereby supporting patient care and treatment options. All interested bidders must carefully review the tender documents for specific submission guidelines and deadlines.

This is a supplies contract in the health and medical services and general supplies sectors. Located in Portugal, Europe, this opportunity is open to firms and consortiums, with an estimated budget of EUR 810.

Published through base_gov_pt, a national government procurement portal. Public procurement tenders follow the country's national bidding regulations and may have specific eligibility and documentation requirements for the supply of goods in the health and medical services sector. Supply contracts typically require bidders to demonstrate product compliance with technical specifications, delivery capacity, and relevant certifications. This contract has already been awarded. The information is published for transparency and market intelligence purposes.